---
title: "UBS Sticks to Their Buy Rating for Gilead Sciences (GILD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301406820.md"
description: "UBS analyst Michael Yee maintained a Buy rating on Gilead Sciences today and set a price target of $175.00. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks, Yee has an average return of 1.1% and a 44.75% success rate on recommended stocks. In addition to UBS, Gilead Sciences also received a Buy from Scotiabank’s Louise Chen in a report issued yesterday. However, on the same day, RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD)."
datetime: "2026-10-09T13:16:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301406820.md)
  - [en](https://longbridge.com/en/news/301406820.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301406820.md)
generator: "portal-rs"
---

# UBS Sticks to Their Buy Rating for Gilead Sciences (GILD)

UBS analyst Michael Yee maintained a Buy rating on Gilead Sciences today and set a price target of $175.00.

Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks, Yee has an average return of 1.1% and a 44.75% success rate on recommended stocks. 

In addition to UBS, Gilead Sciences also received a Buy from Scotiabank’s Louise Chen in a report issued yesterday. However, on the same day, RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [BUZZ-Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead](https://longbridge.com/en/news/301846539.md)
- [Vir Biotechnology partners with Gilead to develop PRO-XTEN dual-masked T-cell engagers for solid tumors](https://longbridge.com/en/news/301842991.md)
- [Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments](https://longbridge.com/en/news/301871452.md)
- [Sandisk Stock Is Falling Thursday: What's Going On?](https://longbridge.com/en/news/301982790.md)
- [Peter Schiff Warns Trump’s ‘Booming’ Stock Market Boast Is a Mirage: 479 Stocks Hit 52-Week Lows on Wednesday, While Only 60 Set Highs](https://longbridge.com/en/news/301958076.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**